Avidity Biosciences (RNA)
(Delayed Data from NSDQ)
$24.36 USD
+0.53 (2.22%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $24.34 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Income Statements
Fiscal Year end for Avidity Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 10 | 9 | 9 | 7 | 2 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 10 | 9 | 9 | 7 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 245 | 188 | 127 | 51 | 20 |
Income After Depreciation & Amortization | -236 | -179 | -118 | -44 | -17 |
Non-Operating Income | 23 | 5 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 7 |
Pretax Income | -212 | -174 | -118 | -44 | -25 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -212 | -174 | -118 | -44 | -25 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -212 | -174 | -118 | -44 | -25 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -245 | -178 | -117 | -44 | -17 |
Depreciation & Amortization (Cash Flow) | -9 | 1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -236 | -179 | -118 | -44 | -17 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 73.01 | 52.16 | 41.43 | 21.66 | NA |
Diluted EPS Before Non-Recurring Items | -2.91 | -3.34 | -2.85 | -2.05 | NA |
Diluted Net EPS (GAAP) | -2.91 | -3.34 | -2.85 | -2.05 | NA |
Fiscal Year end for Avidity Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 2.19 | 2.82 | 2.32 | 2.23 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 2.19 | 2.82 | 2.32 | 2.23 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 68.94 | 61.44 | 54.95 | 59.83 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -66.75 | -58.62 | -52.63 | -57.60 |
Non-Operating Income | NA | 6.30 | 6.27 | 5.61 | 5.20 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -60.44 | -52.36 | -47.03 | -52.39 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -60.44 | -52.36 | -47.03 | -52.39 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -60.44 | -52.36 | -47.03 | -52.39 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 76.05 | 74.10 | 71.39 | 70.43 |
Diluted EPS Before Non-Recurring Items | NA | -0.79 | -0.71 | -0.66 | -0.74 |
Diluted Net EPS (GAAP) | NA | -0.80 | -0.71 | -0.66 | -0.74 |